-
Sarepta Acquires Rights to Gene Therapy Candidate for Limb-Girdle MD
Sarepta Therapeutics is acquiring calpain-3, an investigational gene therapy for the treatment of limb-girdle muscular dystrophy type 2A. Click here to learn more.
What do you think of this news?
Sorry, there were no replies found.
Log in to reply.